Lead Product(s) : Flaxseed
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Ziololek
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Polpharma enhanced its portfolio of OTC & dermatology products, including Linomag (linseed oil), which is indicated for treating skin conditions such as eczema & intertrigo.
Product Name : Linomag
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 10, 2024
Lead Product(s) : Flaxseed
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Ziololek
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Natalizumab
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Sandoz Receives Positive CHMP Opinion for Multiple Sclerosis Biosimilar Natalizumab
Details : Natalizumab biosimilar is mAB that acts as α4 integrin antagonist to prevent leukocyte trafficking into central nervous system, demonstrated high efficacy in Phase III trials by reducing annualized relapse rate, preventing multiple sclerosis lesion accu...
Product Name : Tyruko
Product Type : Antibody
Upfront Cash : Inapplicable
July 24, 2023
Lead Product(s) : Natalizumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Sandoz B2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RVU120
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ryvu Therapeutics
Deal Size : $1.0 million
Deal Type : Agreement
Details : RVU120 is a selective, first-in-class dual CDK8/CDK19 kinase inhibitor that has shown signs of clinical activity in treated patients, as well as efficacy in numerous in vitro and in vivo models of hematologic malignancies and solid tumors.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 07, 2023
Lead Product(s) : RVU120
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ryvu Therapeutics
Deal Size : $1.0 million
Deal Type : Agreement
Lead Product(s) : PKL-021
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Pikralida biopharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Polpharma Partners with Pikralida Biopharmaceutical Start-Up
Details : The partnership involves manufacturing of the drug substance of the clinical candidate PKL-021, needed to support the preclinical research program and the production of an investigational medicinal product for the phase one clinical trial.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 19, 2022
Lead Product(s) : PKL-021
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Pikralida biopharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Valsartan
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : Medical University of Silesia
Deal Size : Inapplicable
Deal Type : Inapplicable
Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2013
Lead Product(s) : Valsartan
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Medical University of Silesia
Deal Size : Inapplicable
Deal Type : Inapplicable
KEY PRODUCTS
Reset All
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
